Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Localized beta radiation therapy targets tumor tissue by delivering beta-emitting radionuclides directly to or near the tumor site. The emitted beta particles cause DNA damage, leading to cell cycle arrest and apoptosis. Selectivity is achieved through carrier molecules that bind to tumor-specific receptors. A key advantage is the cross-fire effect, but potential off-target toxicity due to the long particle range is a major limitation.
Localized beta radiation therapy delivers beta-emitting radionuclides to or near the tumor site. Beta particles cause ionization and excitation in cellular components, particularly DNA, leading to direct and indirect DNA damage, cell cycle arrest, and apoptosis. The cross-fire effect irradiates multiple adjacent cancer cells.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Tissue via Localized Beta Radiation.